Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CID-103 Dose-Escalation and Multi-Dose Study in Adult Chronic ITP
ChiCTR2500115452Phase 2Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CID-103 in immune thrombocytopenic purpura (ITP) (8 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Safety and tolerability of CID-103 and Platelet response. Started Dec 2025; status: completed.
02
Drugs
CID-103
03
Conditions
immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on ChiCTR2500115452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115452.